Biopharma Insights - page 8

Can AI Diagnose Better Than Humans?

A week ago, Microsoft released the AI Diagnostic Orchestrator (MAI-DxO), a platform designed to utilize five large language model agents functioning as a panel of virtual doctors to develop disease …

Continue ›››

Emerging Brain-Computer Interface Industry Across Chips, AI, and Regulation

From surgically embedded chips, adaptive neuroheadsets, and AI-steered interfaces to the intensifying geopolitical contest In summer 2016 Noland Arbaugh, a student of Texas A&M University, suffered spinal cord injury during lake …

Continue ›››

Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome

With DeepMind’s release of AlphaGenome—a deep learning model that can predict the relevance of variants in both coding and non-coding DNA—the so-called “dark genome” has taken center stage in biotech …

Continue ›››

12 Startups Applying AI to Gene Editing: From Custom CRISPR to Zinc-Finger Revivals

In May 2025, clinicians at Children’s Hospital of Philadelphia and Penn Medicine successfully performed a personalized CRISPR-based therapy on a newborn diagnosed with CPS1 deficiency—a rare genetic disorder impairing ammonia clearance in the liver. Built …

Continue ›››

17 More Biomedical Foundation Models

MIT & Recursion's Boltz-2 just launched—here’s a quick scan of 15+ new models spanning chemistry, oncology, trials, and clinical workflows The latest addition arrived yesterday: Boltz-2, an open-source model from MIT …

Continue ›››

Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025 and Beyond

In this report: Intro: The New Framework “AI Drug Discovery” is About Holism "AI Drug Discovery" is About Building Software Access to Data is King Validation is Critical for AI …

Continue ›››

AI-Based Next-Generation-Phenotyping for Rare Disease Diagnosis

Rare diseases, which affect more than 300 million people worldwide, are often difficult to diagnose. Many patients wait five years or more for a correct diagnosis and are misdiagnosed at …

Continue ›››

14 Startups in AI Protein Design: Platforms, Specialists, Modular Tools

A Nobel, a venom cure, and a 200-million-protein database—by late 2024, AI design has earned recognition. David Baker from University of Washington collected the Nobel Prize in Chemistry for structure-guided engineering, sharing the honor …

Continue ›››

AI Meets Clinical Trials: Recent Policy Shifts & Companies to Watch

Today, clinical trials are longer and more data-heavy than a decade ago. At a time of regulatory rethinking, we trace how AI is beginning to orchestrate trial workflows. To know …

Continue ›››

How AI, Graphs, and GraphRAG Are Set to Revolutionize Alzheimer's Gene Research and Treatment

An estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s. Without major medical breakthroughs, that number is projected to rise to 13.8 million in the U.S. by …

Continue ›››

The Infrastructure Layer: 30 Platforms Powering Human-Relevant Drug Development

Infrastructure for large-scale biomedical data — from multi-omics to EHRs — is converging with a growing policy and business case for data-native drug development. In this article: Clinical Data & Real-World …

Continue ›››

Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific

Novotech CRO has released a global market analysis focused on the clinical trial landscape for Idiopathic Pulmonary Fibrosis (IPF), identifying strategic trends for drug developers targeting this chronic and progressive …

Continue ›››